Clinical role of non-invasive assessment of portal hypertension

Massimo Bolognesi, Marco Di Pascoli, David Sacerdoti

Massimo Bolognesi, Marco Di Pascoli, David Sacerdoti, Department of Medicine, University of Padova, I-35128 Padova, Italy

Author contributions: Bolognesi M wrote the manuscript; Di Pascoli M and Sacerdoti D contributed to the intellectual content and revision of the manuscript; all authors approved the final version of the manuscript.

Conflict-of-interest statement: The authors have no conflict of interests.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Massimo Bolognesi, MD, PhD, Associate Professor of Internal Medicine, Department of Medicine, University of Padova, Azienda Ospedaliera Università di Padova, Clinica Medica 5, Via Giustinianani 2, I-35128 Padova, Italy. massimo.bolognesi@unipd.it
Telephone: +39-49-8212383
Fax: +39-49-8754179

Received: August 22, 2016
Peer-review started: August 24, 2016
First decision: September 12, 2016
Revised: September 27, 2016
Accepted: October 30, 2016
Article in press:
Published online: January 7, 2017

Abstract
Measurement of portal pressure is pivotal in the evaluation of patients with liver cirrhosis. The measurement of the hepatic venous pressure gradient represents the reference method by which portal pressure is estimated. However, it is an invasive procedure that requires significant hospital resources, including experienced staff, and is associated with considerable cost. Non-invasive methods that can be reliably used to estimate the presence and the degree of portal hypertension are urgently needed in clinical practice. Biochemical and morphological parameters have been proposed for this purpose, but have shown disappointing results overall. Splanchnic Doppler ultrasonography and the analysis of microbubble contrast agent kinetics with contrast-enhanced ultrasonography have shown better accuracy for the evaluation of patients with portal hypertension. A key advancement in the non-invasive evaluation of portal hypertension has been the introduction in clinical practice of methods able to measure stiffness in the liver, as well as stiffness/congestion in the spleen. According to the data published to date, it appears to be possible to rule out clinically significant portal hypertension in patients with cirrhosis (i.e., hepatic venous pressure gradient ≥ 10 mmHg) with a level of clinically-acceptable accuracy by combining measurements of liver stiffness and spleen stiffness along with Doppler ultrasound evaluation. It is probable that the combination of these methods may also allow for the identification of patients with the most serious degree of portal hypertension, and ongoing research is helping to ensure progress in this field.

Key words: Portal hypertension; Splenic stiffness; Liver stiffness; Splenic arterial resistance indices; Sonography; Doppler ultrasound; Cirrhosis; Transient elastography; Esophageal varices

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This Editorial analyzes the newest and promising methods for estimating portal pressure non-
invasively in cirrhotic patients with portal hypertension. Measurements of liver and spleen stiffness, combined with Doppler ultrasound evaluation, allow for the identification of patients without clinically-significant portal hypertension and are also promising for estimation of the degree of portal pressure in patients with portal hypertension.


INTRODUCTION

Measurement of portal pressure is pivotal in the evaluation of patients with liver cirrhosis. Indeed, portal hypertension is a complication of cirrhosis that affects prognosis and the natural history (disease stage). Portal hypertension is the main etiology underlying the opening of collateral circulation and the onset of hyperdynamic circulatory syndrome, which can result in esophageal varices (EV), gastrointestinal bleeding, ascites, hepatoportal syndrome, spontaneous bacterial peritonitis and/or hepatic encephalopathy. Therefore, upper gastrointestinal endoscopy and measurement of portal pressure are recommended for patients with suspected liver cirrhosis and portal hypertension. Moreover, the measurement of portal pressure represents the only valid method currently available for evaluation of effectiveness of portal hypertension therapies (pharmacological, surgical, interventional radiology).

CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION

Increase in portal pressure has been shown to be clinically significant (clinically significant portal hypertension, CSPH) when it corresponds to a porto-hepatic gradient of ≥ 10 mmHg. CSPH is considered the threshold beyond which complications like EV and ascites may develop. However, in the evaluation of portal hypertension, it is not sufficient to merely determine the presence or absence of CSPH. Indeed, the degree of portal hypertension defines different levels of risk, with progressively worse prognostic significance.

Risk of EV, ascites and decompensation after surgery for hepatocellular carcinoma is associated with portal pressure > 10 mmHg, while risk of bleeding of EV is associated with a portal pressure of ≥ 12 mmHg. Portal pressure > 16 mmHg is reported as correlated with survival, first clinical decompensation in patients with varices, and higher risk of esophageal rebleeding and mortality in patients with decompensated cirrhosis; higher than 20 mmHg is correlated with failure to control bleeding in patients with active bleeding from varices and to mortality, > 22 mmHg is correlated with mortality in patients with alcoholic cirrhosis and acute alcoholic hepatitis, and > 30 mmHg is correlated with spontaneous bacterial peritonitis. In contrast, improvement of portal hypertension is associated with improved prognosis. In particular, a reduction in portal pressure to a level of < 12 mmHg, or to at least 20% of the baseline values, is necessary to obtain clinical efficacy of portal hypertension therapy. It is clear, therefore, that when portal hypertension is suspected in patients with liver cirrhosis, it is not only necessary to know whether CSPH is present but also to quantify the level of portal hypertension and, further, to evaluate the change in portal pressure over time.

MEASUREMENT OF PORTAL PRESSURE: THE HEPATIC VENOUS PRESSURE GRADIENT

The actual reference method for the measurement of portal pressure is measurement of the hepatic venous pressure gradient (HVPG), an indirect estimate of portal pressure obtained by use of catheterization of the hepatic veins. It allows measurement of the level of sinusoidal pressure by calculating the difference between the pressure in a hepatic vein that has been inserted with the occluding catheter and free pressure. In the cirrhosis condition, portal hypertension is mainly due to sinusoidal and post-sinusoidal hypertension, with the sinusoidal pressure corresponding to the pressure in the portal vein. Introduction of balloon catheters to this measurement approach has resulted in marked improvement in reliability of the measurement.

HVPG is an indirect method, which is only able to correctly evaluate portal pressure in patients with increased portal pressure at the sinusoidal level (i.e., cirrhosis), and it has no value in patients with pre-sinusoidal and pre-hepatic portal hypertension. Yet, detection of its normality can sometimes help in differential diagnosis of those forms of pre-hepatic portal hypertension.

With this limitation, HVPG, if executed according to the guidelines, is a safe and reproducible technique, and has emerged as the reference method for measurement of the pressure gradient between the portal vein and the inferior vena cava in cirrhosis (sinusoidal portal hypertension). Unfortunately, the method is invasive and relies on the commitment of significant hospital resources, equating to a considerable cost and requiring experienced staff. As such, it is routinely performed in only a few centers, particularly those specializing in the treatment of portal hypertension.
hypertension\textsuperscript{[10]}.

**NON-INVASIVE ESTIMATION OF PORTAL PRESSURE**

Non-invasive methods that can be used reliably to determine the presence and estimate the degree of portal hypertension have been in great demand for at least 30 years. Despite substantial efforts to generate such a method, up until a few years ago only disappointing and unsatisfactory results were obtained.

Since the primary cause of portal hypertension is the mechanical increase in intrahepatic resistance due to fibrosis and distortion of liver architecture, it is reasonable to assume that non-invasive parameters of liver fibrosis may indicate the presence of portal hypertension.

**ESTIMATION OF PORTAL HYPERTENSION BY BIOCHEMICAL AND MORPHOLOGICAL PARAMETERS**

A number of the biochemical and morphological parameters that have been proposed for evaluation of the degree of liver fibrosis have been analyzed for their potential in use for the evaluation of portal hypertension and/or the presence of EV\textsuperscript{[11]}. Even if there is a broad correlation between these indices and portal pressure or the presence of EV, confirming the role of liver fibrosis in the genesis of this condition, it is a fact that the low coefficients of the correlations do not support clinical use of these parameters for this purpose. Various indices have also been proposed\textsuperscript{[3,12,13]}. The platelet count/spleen diameter ratio (Plt/Spl) was reported to be independently associated with the presence of EV, as shown in a multivariate analysis. A Plt/Spl cut-off value of 909 had 100% negative predictive value of 909 had 100% negative predictive value for diagnosis of EV\textsuperscript{[14,15]}. Another study determined that this parameter is also related to the presence of portal hypertension\textsuperscript{[16]}. A model combining albumin, aspartate aminotransferase (AST) and the international normalized ratio (INR) had an area under the receiver operating characteristic curve (AUROC) of 0.952 for prediction of CSPH in a group of patients with compensated cirrhosis\textsuperscript{[17]}.

In a study by Sebastiani et al\textsuperscript{[18]}, a combination of the Lok index (an index derived by AST and alanine aminotransferase (ALT) levels, platelet counts and prothrombin time (PT)-INR; using a cut-off of 1.5) and the Forns’ index (an index derived by age, platelet counts, gamma-glutamyl transferase (GGT) and cholesterol; using a cut-off of 8.8) had an AUROC of 0.80 (95%CI: 0.76-0.84) and a high negative predictive value (> 90%) for excluding clinically-relevant EV\textsuperscript{[19]}.

Overall, the results for the proposed parameters and indices have not been satisfactory\textsuperscript{[3]}. Serum markers may be useful as a first-line tool to identify cirrhotic patients in whom the risk of clinically-relevant EV is trivial\textsuperscript{[17]}. However, the possibility of replacing upper endoscopy with simple serum non-invasive markers is still not practical for the vast majority of patients\textsuperscript{[3,11,13,17,18]}. Accordingly, the biochemical/morphological tests may be of help to diagnose patients with suspected CSPH, but not to estimate the degree of portal pressure. These tests do not allow for clinical decisions on their own, nor can they be used alone in a clinical context; although, they may be sufficient in use as a first-level test\textsuperscript{[20]} (laboratory tests require no clinical skillfulness, distinctive from Doppler ultrasound and measurement of tissue stiffness), but their use would not exempt a clinician from undertaking further analysis with more accurate tests.

**ESTIMATION OF PORTAL HYPERTENSION BY DOPPLER ULTRASOUND TECHNIQUES**

The introduction of ultrasound and Doppler techniques generated great expectations in the 1990s for non-invasive assessment of portal hypertension. Doppler ultrasound evaluation was a major step forward in the clinical evaluation of patients with portal hypertension. Indeed, many parameters indicating the presence of portal hypertension could be identified non-invasively, including the presence of collateral vessels, spleen enlargement, ascites, change in the portal vein parameters (e.g. increase in diameter, disappearance of caliper variation during respiration, decrease in blood flow velocity, increase in the congestion index), increase in hepatic and splenic arterial resistance indices, and decrease in the damping index of hepatic veins\textsuperscript{[5,12,20–22]}.

Scores obtained by the combinations of measuring portal vein blood velocity, portal vein diameter, the hepatic artery resistance index and splenic artery resistance index\textsuperscript{[4,12,23–26]} were proposed and demonstrated to be useful in the clinical monitoring of patients with cirrhosis and portal hypertension.

Some of these parameters, such as the presence of collateral circulation in patients with cirrhosis, can be considered as having a specificity of 100% for the diagnosis of CSPH\textsuperscript{[2]}; although, all of these parameters have low diagnostic sensitivity for identifying the condition.

In patients with known cirrhosis, Doppler ultrasound has > 80% specificity for diagnosis of CSPH, but sensitivity does not exceed 40%-70%, particularly in compensated patients\textsuperscript{[5]}. Therefore, while the presence of one or more Doppler ultrasound signs can
establish the presence of CSPH, their absence cannot exclude it. Moreover, Doppler ultrasound is not useful for evaluating the effect of pharmacological therapy on portal hypertension, as vasoactive drugs used in the therapy of portal hypertension modify Doppler parameters (i.e., vascular blood velocity, resistance indices) per se, in a manner independent of the final modification of portal pressure.

On the contrary, Doppler parameters may have major utility in the evaluation of the effect of surgical therapy and of liver transplantation on portal hypertension. Indeed, in these conditions, normalization of portal hemodynamics and of splenic Doppler resistance indices has been proposed as confirmatory for having achieved a good resolution of portal hypertension after surgery\(^{[27]}\).

Thus, although indispensable in the evaluation and monitoring of patients with cirrhosis and portal hypertension, Doppler ultrasonography cannot be used on its own as a screening method to exclude CSPH, nor as a method for monitoring portal pressure over time. Doppler ultrasound, however, does detect signs, such as portal-collateral circulation, ascites and portal vein thrombosis, that, if present, allow for a certain diagnosis of CSPH.

Color Doppler ultrasonography is a useful non-invasive modality for assessing gastric, duodenal and rectal varices\(^ {28-32}\). Contrast-enhanced ultrasonography analysis of transit time of microbubble contrast agent through the liver has demonstrated that a decrease in the transit time between the hepatic vein and the hepatic artery or the portal vein (a sign of porto-hepatic shunting) is related to the degree of portal hypertension in cirrhosis\(^ {12,21,32}\). Moreover, a relation has been reported for the presence of portal hypertension and a number of other parameters derived by the analysis of time-intensity curves of contrast agent in the various liver structures; these parameters include regional hepatic perfusion\(^ {33}\), portal vein/hepatic artery strength ratio, area under the portal vein/hepatic artery time-intensity curve ratio, and portal vein/hepatic artery wash-in perfusion slope ratio\(^ {34}\). Unfortunately, most of the correlations reported between these parameters and portal pressure are weak, indicating that they cannot predict the presence of CSPH in single patients with sufficient accuracy.

Recently, a new non-invasive approach to quantify portal pressure has been proposed that is based upon subharmonic emission from ultrasound contrast agents\(^ {35,36}\). The changes of subharmonic signal amplitude are reported as correlating with portal pressure changes\(^ {36}\); moreover, Eisenbrey et al.\(^ {37}\) demonstrated that subharmonic-aided pressure estimation (SHAPE) was in good overall agreement with HVPG (\(r = 0.82\)). This method seems promising and deserves further study.

### ESTIMATION OF PORTAL PRESSURE BY THE MEASUREMENT OF LIVER STIFFNESS

Another important advancement in the non-invasive assessment of portal hypertension has been the introduction of non-invasive measurement of liver stiffness (LS) by transient elastography (TE). Originally proposed and designed as a non-invasive approach for detecting the presence of fibrosis in the liver, after initial doubts, the method has gradually imposed itself as a routine method used in the clinical evaluation of patients with chronic liver disease. TE has proven sensitive for estimating the absence of liver fibrosis or the presence of high-degree liver fibrosis, yet patients with moderate fibrosis remain more difficult to assess\(^ {26}\). TE has also been shown to be related to the degree of portal pressure\(^ {10,38,39}\). Such a correlation is somewhat expected because liver fibrosis is the first and main determinant both of tissue stiffness and of intrahepatic resistance to portal blood flow\(^ {33}\). LS can increase independently of fibrosis due to food ingestion, inflammation, cholestasis and liver congestion\(^ {33}\). Even with the limitations cited above, a number of studies have demonstrated that the related method allows not only for estimation of liver fibrosis but also determination of CSPH presence\(^ {13,40,41}\). In patients with chronic liver disease, LS can predict CSPH (HVPG \(\geq 10\) mmHg) with a very high accuracy, having an AUROC of 0.945 (95%CI: 0.904-0.987); when the cut-off value was set at 21 kPa, this procedure accurately predicted CSPH in 92% of the patients for whom LS was successful\(^ {40}\). Lemoine et al.\(^ {41}\) confirmed that LS can predict CSPH, but highlighted that the cut-off is higher, with a better performance, in alcoholic patients; in particular, the AUROC for diagnosis of CSPH was reported as 0.76 ± 0.07 in patients with hepatitis C virus (HCV) infection (best cut-off at 20.5 kPa) and 0.94 ± 0.03 (best cut-off at 34.9 kPa) in alcoholic patients\(^ {41}\).

These results justify the proposal to use this method in clinical practice for identifying patients with CSPH\(^ {5}\). Therefore, TE can be used as a screening method for CSPH in patients with compensated liver cirrhosis\(^ {2,5}\).

Vizzutti et al\(^ {39}\) showed that the correlation between LS and portal pressure in cirrhosis is very good up to 10-12 mmHg, while it is substantially lacking for higher values. This finding has been explained by the fact that - while in the early stages of the disease the main factor determining portal hypertension is liver fibrosis, therefore it is well related to portal pressure - once CSPH is established, the progression of portal hypertension depends not only on liver fibrosis but also on other factors, especially those related to the hyperdynamic circulation, the splanchnic vasodilatation and the resistance in portosystemic collaterals\(^ {42-46}\).
Unfortunately, these factors are not estimated by LS\textsuperscript{[10,16,39]}.

According to the collective data, TE can be very useful for ruling out or ruling in CSPH\textsuperscript{[5]}, however, the technique is not accurate enough to replace HVPG in quantifying the exact severity of portal hypertension\textsuperscript{[5]}. Furthermore, TE is unlikely to be useful in monitoring hemodynamic response to drug therapy, the effect of which is mediated primarily by decreases in splanchnic blood flow and partially by modifications in hepatic and collateral resistance, and not by improvements in hepatic fibrosis and liver stiffness\textsuperscript{[38]}.

LS has been demonstrated to be as effective as HVPG for predicting clinical decompensation and portal hypertension-related complications in patients with chronic liver disease\textsuperscript{[45]}. The usefulness of LS in predicting portal hypertensive complications was confirmed by Kitson et al\textsuperscript{[46]}.

In recent years, additional techniques have been proposed for the evaluation of LS, each of which appear to overcome some of the limitations presented by traditional TE\textsuperscript{[47,48]}; these include acoustic radiation force impulse imaging (ARFI) and shear-wave velocity estimation. In particular, the real-time shear-wave elastography (SWE) allows for real-time viewing of the area under investigation, contrary to TE which is done blindly, as well as integration of the assessment of TE with traditional ultrasound and Doppler\textsuperscript{[1,12,21,47,49-51]}. In this context, it may be possible to integrate the measurement of LS with Doppler ultrasound parameters and, therefore, improve the accuracy of portal hypertension evaluation. The reported technical success rate of SWE is significantly better than that of TE\textsuperscript{[53]}. Choi et al\textsuperscript{[53]} also proposed that non-invasive measurement of LS by SWE may be useful for monitoring efficacy of the medical therapy of portal hypertension.

**ESTIMATION OF PORTAL HYPERTENSION BY THE MEASUREMENT OF SPLEEN STIFFNESS**

A very noteworthy advancement in this field is the application of non-invasive evaluation of parenchymal stiffness (via TE, ARFI and SWE) in the spleen\textsuperscript{[16,54,55]}. An interesting study\textsuperscript{[16]} showed that in patients with HCV-related cirrhosis, there is a very good correlation between HVPG and spleen stiffness (SS) ($r^2 = 0.78$), with a correlation that is maintained even when portal pressure is $> 10$ mmHg, which contrasts with LS. This study suggests that SS increases in close parallel with the progression of portal hypertension from the early to the late stages of cirrhosis\textsuperscript{[10]}.

Similarly to LS, SS measurement has also been reported as useful for predicting of clinical complications in compensated cirrhosis\textsuperscript{[56]}. In patients with HCV-related cirrhosis, a SS and model for end-stage liver disease (MELD) predictive model represented an accurate predictor of clinical decompensation, with accuracy at least equivalent to that of HVPG\textsuperscript{[56]}. A value for SS of $< 54$ kPa ruled out the risk of complications in the subsequent 2 years\textsuperscript{[56]}. SS has been shown to decrease after orthotopic liver transplantation, when portal hypertension is resolved\textsuperscript{[27]}. This is a behavior similar to splenic resistance indices\textsuperscript{[27]}.

Although not all of the subsequent studies yielded such reassuring results\textsuperscript{[51,52]}, this study highlighted that spleen parameters probably reflect the levels of portal hypertension more accurately, due to the peculiar modifications that occur in the spleen during portal hypertension as a result of congestion and hyperplasia\textsuperscript{[58]}. In cirrhosis, splenomegaly is not only due to passive congestion but also to tissue hyperplasia, and is characterized by a combination of angiogenesis, fibrogenesis, and enlargement and hyperactivation of the splenic lymphoid compartment\textsuperscript{[16,58]}. This condition of hyperplasia, with increased flow, participates in the hyperdynamic circulatory syndrome of portal hypertension\textsuperscript{[59]}.

Stiffness and hemodynamics of the spleen are probably sensitive sensors of portal pressure and of portal vein resistance. Therefore, it seems that the next route to follow will be the combination of SS with the Doppler splenic resistance indices, and possibly platelet count and spleen size. Indeed, individually, these parameters have shown better accuracy in the prediction of portal hypertension. SS is probably related to splenic congestion due to portal hypertension in an organ with a rigid capsule. The platelet count/spleen diameter ratio is probably the simplest index for determining the presence of portal hypertension and EV\textsuperscript{[14-16,59,60]}. Doppler splenic resistance indices are related to portal blood flow resistance and to HVPG\textsuperscript{[22,24]}.

As evidence for the central role of splenic hemodynamics in portal hypertension, a few studies have shown the usefulness of combining the value of LS with splenic parameters to improve the identification of patients with portal hypertension. Among these parameters are the LS-spleen diameter to platelet ratio score (LSPS)\textsuperscript{[13,16,59]} and the portal hypertension risk score, the latter of which combines LS, sex and spleen diameter/platelet count ratio\textsuperscript{[87]}. This portal hypertension risk score had the highest AUROC value (0.935), as compared with LS alone or LSPS, for identifying patients with CSPH.

**LIMITATIONS OF LS AND SS MEASUREMENT**

A limitation of this method is the significant number of patients for whom the measurement of LS and/or SS could not be completed or yielded unreliable results. Reported, valid measurement of LS is not obtained.
in approximately 20% of patients\cite{16,19,47}. TE cannot be performed in patients with ascites, and the failure rate of TE is generally higher in obese patients\cite{47}. Aminotransferase flares, food intake, extrahepatic cholestasis, steatosis, increased central venous pressure and the use of beta-blockers can influence the accuracy of LS assessment by TE\cite{36,62}. Moreover, LS and SS measurement are considered reliable for estimating portal hypertension only when the coefficient of variation among the successful measurements in a single patient is low\cite{51,52}. In the study by Elkrief et al\cite{52}, the designation of excellent accuracy (i.e., patients with variation coefficient of TE measurement < 10%) was achieved in < 50% of the patients. Procopet et al\cite{51} proposed that SWE measurement of LS can be considered “highly reliable” only when measurements have a coefficient of variation < 10% and a depth of measurement < 5.6 cm; when these criteria are fulfilled, the rate of patients considered well-classified for the presence or absence of CSPH is close to 100%.

**MAGNETIC RESONANCE IMAGING AND COMPUTED TOMOGRAPHY**

Other methods have been proposed for non-invasive assessment of LS related to portal hypertension, namely magnetic resonance elastography, quantitative magnetic resonance imaging and computed tomography (CT). Although very interesting, at present these methods cannot be recommended as routine for measuring LS and SS. Magnetic resonance elastography can decompose tissue viscoelastic parameters into different components, including stiffness, elasticity and viscosity, allowing for better differentiation of fibrosis from congestion\cite{63}. CT has the hypothetical capacity to assess portal pressure by using computational fluid dynamic modeling\cite{64}, and has already been proposed for use in evaluation of the fractional flow coronary reserve\cite{65}. While magnetic resonance techniques are very promising\cite{66,67}, they are too expensive and the use of CT also seems impractical due to the high cost and the time-consuming nature of
the computational fluid dynamic modeling.

NON-INVASIVE ESTIMATION OF THE PRESENCE OF EV

A number of studies have shown that LS and SS would also be able to identify, with acceptable accuracy, patients with EV at risk of bleeding\(^1\).\(^{16,60}\).

The findings of these studies, however, have been contradicted by other research groups\(^1\).\(^{13,52,69}\). The identification of patients with risk of bleeding from EV may be better with the measurement of SS\(^1\), and particularly as related to LS\(^1\).\(^{60}\).

Considering that the measurement of LS and SS can be considered a good method to identify patients with CSPH, and that EV develops only in the presence of CSPH, it may be reasonable to propose the measurement of LS and SS as a screening method for identifying chronic liver disease patients with HVPG < 10 mmHg (these patients should not have EV). Also, it is important to note that CSPH is a necessary, but not sufficient, condition for development of EV\(^1\).\(^{19}\).

Therefore, measurement of LS and SS can exclude the need for a screening esophagogastroduodenoscopy, but cannot identify who among the patients with CSPH is at risk of esophageal bleeding\(^1\).\(^{16,60}\).

According to the Baveno VI criteria, TE and platelet count may be used to discriminate such patients, without the need for screening varices\(^2\). On the other hand, imaging analyses have shown that collateral circulation is sufficient for ruling-in CSPH in patients with compensated advanced chronic liver diseases of all etiologies\(^2\).

A hypothetical algorithm of non-invasive methods for screening and evaluation of CSPH and to discriminate patients with or without a need for screening varices is presented in Figure 1.

CONCLUSION

According to the data published to date in the publicly available literature, it appears possible to rule-out CSPH with a clinically-acceptable accuracy through the combination of LS and SS measurements\(^1\).\(^{16,60,50,59,73}\) along with Doppler ultrasound evaluation. It is probable that the combination of these methods may also allow for the identification of patients with the most serious degree of portal hypertension. Indeed, progress is being made in this field.

To conclude, however, advancement in the non-invasive evaluation of portal hypertension has included the introduction of methods to clinical practice that are able to measure stiffness in the liver and stiffness/congestion in the spleen. These methods, combined with Doppler ultrasound evaluation, allow for the identification of patients without CSPH. They are also promising for their ability to estimate the degree of portal pressure in patients with CSPH.

REFERENCES

1. Castera L, Garcia-Tsao G. When the spleen gets tough, the varices get going. *Gastroenterology* 2013; 144: 19-22 [PMID: 23164570 DOI: 10.1053/j.gastro.2012.11.015]
Bolognesi M et al. Non-invasive assessment of portal hypertension  


Ultrasound-based shear wave elastography (U-SWE) is a non-invasive technique used to assess liver stiffness, which is a surrogate marker for liver fibrosis and cirrhosis. The technique involves applying a burst of high-frequency ultrasound to generate a shear wave, which propagates through the liver tissue. The stiffness of the liver is then calculated from the propagation speed of this shear wave, enabling non-invasive assessment of liver fibrosis.

The role of U-SWE in the assessment of portal hypertension is becoming increasingly recognized. Portal hypertension is a condition characterized by an increase in the pressure gradient between the portal vein and the systemic veins, typically due to liver cirrhosis. This condition can lead to the development of complications such as esophageal varices, which are dilated veins in the esophagus that can bleed if ruptured.

Recent studies have demonstrated the potential of U-SWE in evaluating the resolution of portal hypertension after liver transplantation. For example, in a study by Chan et al. (2015), U-SWE was used to assess the resolution of portal hypertension in patients who underwent liver transplantation. The study showed that U-SWE could effectively evaluate the changes in liver stiffness before and after transplantation, providing valuable information for the management of these patients.

Another study by Palaniyappan et al. (2016) investigated the use of U-SWE in the assessment of portal hypertension and its relationship with other indices of liver function. The study found that U-SWE could accurately estimate liver stiffness in patients with liver cirrhosis, providing additional insights into the severity of liver disease.

In summary, U-SWE is a promising non-invasive tool in the assessment of portal hypertension. It offers a safe, easy-to-use, and cost-effective method for evaluating liver stiffness, which is crucial in the management of patients with liver cirrhosis and portal hypertension. Further research is needed to validate the use of U-SWE in a larger patient population and to explore its potential as a routine clinical tool.


**P- Reviewer:** Fernandez-Rodriguez CM, Fierbinteanu-Braticevici C, La Mura V, Makisalo H, Maruyama H, Sato T, Tantau M

**S- Editor:** Gong ZM  **L- Editor:** A  **E- Editor:** Wang CH